How Japan's Biennial NHI Drug Price Revision Works

For decades, Japan's drug price revision cycle was one of the most predictable rhythms in global pharma market access. Every two years, the Ministry of Health, Labour and Welfare (MHLW) would survey actual transaction prices — the prices at which drugs were actually purchased by hospitals and pharmacies — and use the gap between those survey prices and the official NHI listed prices to set new, lower official prices. That biennial architecture defined how companies planned launches, modeled revenue, and approached Chuikyo negotiations.

That architecture has since changed fundamentally. But understanding the original biennial system is essential context for grasping how Japan's pricing environment operates today — and how it is likely to evolve further.

How the Classic Biennial Revision Worked

The biennial price revision followed a structured sequence rooted in a single core principle: Japan's NHI listed prices should track actual market transaction prices. When a drug's NHI listed price is, say, ¥100 per tablet but hospitals are actually buying it for ¥85, the system treats that ¥15 gap as evidence that the listed price is above the real market value. The revision closes that gap.

The key steps in the biennial cycle were:

Market price survey (yakka chosa): MHLW collects actual transaction price data from wholesalers, hospitals, and pharmacies. This is a comprehensive survey covering the vast majority of NHI-listed drugs.
Gap calculation: The difference between each drug's listed price and its weighted average transaction price is calculated. This gap is called the "R-zone" discrepancy.
Chuikyo deliberation: The Central Social Insurance Medical Council reviews aggregate survey results, agrees on revision rules, and determines how much of the gap to close. Historically, Japan closed approximately the full gap minus a small retained margin.
New price announcement: MHLW publishes new official NHI listed prices, typically effective April 1 of the revision year.

Under the biennial model, revisions occurred in even-numbered fiscal years (e.g., FY2014, FY2016, FY2018, FY2020). Odd years were, in principle, stable — giving companies a two-year window to plan around a fixed price.

The Shift to Annual Revisions

Japan introduced "off-year" revisions for a limited set of high-expenditure drugs beginning in 2021. The original trigger was concern that certain drugs — particularly high-cost biologics and novel specialty drugs — were generating expenditure far above the NHI forecasts used to set initial prices, and waiting two full years to correct listed prices was fiscally untenable.

By FY2022 and beyond, annual revisions became effectively standard practice. The FY2026 revision, implemented April 1, 2026, applied an average price reduction of 4.02% across approximately 15,800 NHI-listed products. Among those, roughly 61% saw price cuts and 12% saw price increases (the latter primarily due to a 3.5% minimum price floor increase applied to low-cost generics that had fallen below sustainable thresholds).

What Changes Each Revision Cycle

Beyond the standard market survey-based repricing, each revision cycle also includes rule-based adjustments:

Market Expansion Repricing (MER): When a drug's actual sales significantly exceed the MHLW forecast at original pricing, automatic price reductions are triggered — historically at defined multiples of forecast overage.
G1 repricing: Off-patent long-listed products face progressive price reduction toward a reference floor. In FY2026, Japan expanded G1 eligibility to include all long-listed products past the replacement period, regardless of their generic substitution rate.
Patent Period Price Maintenance Program (PMP): Branded drugs under patent receive temporary relief from repricing, but when the patent expires and generics list, accumulated PMP must be returned. The FY2026 revision saw significant PMP return activity.
Cost-effectiveness assessment (CEA): A subset of high-expenditure drugs undergoes formal health technology assessment. In FY2026, 49 drugs were reviewed, with 37 receiving an average additional reduction of approximately 5.3%.

What This Means for Planning and Monitoring

The shift from biennial to annual revisions has compressed the planning window for pharma teams significantly. Price forecasts that once held for 24 months now need to be rebuilt annually. Launch timing relative to the April revision date has also become a more sensitive variable, as a drug listed just before revision inherits revised prices within months.

Real-time visibility into listed prices across the NHI formulary is more valuable than ever. Teams that can monitor price trends at the drug level — and identify early signals of MER or G1 exposure — gain a meaningful advantage in forecast accuracy and negotiation preparation.

NHI Price Wire provides up-to-date listed price data for 17,000+ Japan NHI drugs, helping market access teams track revision impacts the moment they take effect — explore the dashboard.